The DOI matches its Crossref record.
Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
Open accessAbstract
Prostate carcinoma is the second leading cause of death from malignancy in men in the United States. Prostate cancer cells express type I insulin-like growth factor receptor (IGF-IR) and prostate cancer selectively metastazises to bone, which is an environment rich in insulin-like growth factors (IGFs), thereby supporting a paracrine action for cancer cell proliferation. We asked whether the IGF-IR is coupled to tumorigenicity and invasion of prostate cancer. When rat prostate adenocarcinoma cells (PA-III) were stably transfected with an antisense IGF-IR expression construct containing the ZnSO4-inducible metallothionein-1 transcriptional promoter, the transfectants expressed high levels of IGF-IR antisense RNA after induction with ZnSO4, which resulted in dramatically reduced levels of endogenous IGF-IR mRNA. A significant reduction in expression both of tissue-type plasminogen activator and of urokinase-type plasminogen activator occurred in PA-III cells accompanying inhibition of IGF-IR. Subcutaneous injection of either nontransfected PA-III or PA-III cells transfected with vector minus the IGF-IR insert into nude mice resulted in large tumors after 4 weeks. However, mice injected with IGF-IR antisense-transfected PA-III cells either developed tumors 90% smaller than controls or remained tumor-free after 60 days of observation. When control-transfected PA-III cells were inoculated over the abraded calvaria of nude mice, large tumors formed with invasion of tumor cells into the brain parenchyma. In contrast, IGF-IR antisense transfectants formed significantly smaller tumors with no infiltration into brain. These results indicate an important role for the IGF/IGF-IR pathway in metastasis and provide a basis for targeting IGF-IR as a potential treatment for prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Samani, A. A., Yakar, S., LeRoith, D., & Brodt, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0001 · Cited by 1,005
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A., & Friend, K. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0399 · Cited by 843
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Peruzzi, F., Prisco, M., Dews, M., Salomoni, P., Grassilli, E., Romano, G., Calabretta, B., & Baserga, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7203 · Cited by 498
A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics
Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., & Muramatsu, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2682 · Cited by 378
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
Mantzoros, C., Tzonou, A., Signorello, L., Stampfer, M., Trichopoulos, D., & Adami, H.-O. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.520 · Cited by 366
Bubendorf, L., Kolmer, M., Kononen, J., Koivisto, P., Mousses, S., Chen, Y., Mahlamaki, E., Schraml, P., Moch, H., Willi, N., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.20.1758 · Cited by 350
Hormonal Predictors of Prostate Cancer: A Meta-Analysis
Shaneyfelt, T., Husein, R., Bubley, G., & Mantzoros, C. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.847 · Cited by 310
Adhami, V. M., Siddiqui, I. A., Ahmad, N., Gupta, S., & Mukhtar, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2840 · Cited by 296
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
“Signaling by IGF1 is of major mechanistic and biological significance (Burfeind et al. 1996, Pollak et al. 1998, Wolk et al. 1998, Nickerson et al. 2001).”
BackgroundTriple helix formation and the antigene strategy for sequence-specific control of gene expression
Praseuth, D., Guieysse, A. L., & Hélène, C. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00149-9 · Cited by 262
Shi, P., Chandra, J., Sun, X., Gergely, M., Cortes, J. E., Garcia‐Manero, G., Arlinghaus, R. B., Lai, R., & Amin, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00795.x · Cited by 24
Metadata
- Authors
- Burfeind, P., Chernicky, C. L., Rininsland, F., Ilan, J., & Ilan, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-07-09
- Volume
- 93
- Issue
- 14
- Pages
- 7263-7268
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2005873549
- Cited by
- 238
- References
- 0
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.